Immunogenicity and immune privilege of corneal allografts.
Immunogenicity and immune privilege of corneal allografts.
复制标题
DOI：
10.1159/000099279
复制
发表时间：
2007-01-01
期刊：
影响因子：
--
通讯作者：
Niederkorn, Jerry Y
中科院分区：
文献类型：
--
作者：
Hori, Junko;Niederkorn, Jerry Y
与所有其他形式的器官移植相比，角膜异体移植具有显著的成功率。在常规角膜移植术中，不使用HLA匹配和全身免疫抑制药物，但90%的无并发症移植存活。半个多世纪前，角膜异体移植的成功得到了认可，并产生了“免疫特权”一词。对异体角膜移植物免疫特权的最初解释将免疫排斥的逃避归因于角膜移植物床的无血管和淋巴性质，这将角膜移植物与免疫器官隔离开来。在过去的20年里，角膜移植动物模型的广泛应用揭示了角膜免疫特权的机制，并揭示了角膜异体移植的成功是由于角膜移植床和角膜本身的特性的结合。
Corneal allografts enjoy a remarkable success rate when compared to all other forms of organ transplants. In routine keratoplasties, HLA matching and systemic immunosuppressive drugs are not employed, yet 90% of the uncomplicated transplants survive. The success of corneal allografts was recognized over half a century ago and led to the term 'immune privilege'. The original explanation for the immune privilege of corneal allografts attributed the escape of immune rejection to the avascular and alymphatic nature of the corneal graft bed, which sequestered the corneal allograft from the immune apparatus. In the past 20 years, the widespread use of animal models of keratoplasty has shed light on the mechanisms of corneal immune privilege and has revealed that the success of corneal allografts is due to a combination of properties of the corneal graft bed and the cornea itself.